Oslo, 28 November 2025: Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") announces that the Company and its Chief Financial Officer (CFO), Lars Hjarrand, today has entered into an agreement whereby Hjarrand will step down as CFO of the Company to pursue new opportunities outside the Company. Director of Group Accounting, Pål Zimmermann Vonen will assume the role as acting CFO until a new permanent CFO has been appointed.
 

"We wish to express our gratitude to Lars for his dedicated service and valuable contributions to the Company's growth and development, and wish him all the best for the future", said Kathrine Gamborg Andreassen, CEO of Navamedic.
 

For further information, please contact:
 

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com.

About Navamedic
Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, addiction, metabolism and antibiotics, to empower people to live healthier and more fulfilling lives.
What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit www.Navamedic.com
 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.